Similar to our results, it has been reported that lower levels of IGF2 in plasma are associated with more severe liver fibrosis in patients with non-alcoholic fatty liver disease (Ajmera et al. 2017). This evidence concerns the gene IGF2 and metabolic dysfunction-associated steatotic liver disease.